Press Releases June 19, 2025: MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 Marketing Authorization…MaaT PharmaJune 19, 2025
Press Releases June 2, 2025: MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency…MaaT PharmaJune 2, 2025
Press Releases May 13, 2025: MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 Positive…MaaT PharmaMay 13, 2025
Press Releases April 28, 2025: MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity…MaaT PharmaApril 28, 2025
Press Releases March 31, 2025: MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve…MaaT PharmaMarch 31, 2025
Press Releases March 18, 2025: MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial…MaaT PharmaMarch 18, 2025
Press Releases March 11, 2025: MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013 MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for…MaaT PharmaMarch 11, 2025